Covered when product‑specific conditions and any required prior/concomitant therapies or documentation are met (see each product entry).
Talzenna: Coverage for metastatic castration‑resistant prostate cancer requires use in combination with enzalutamide.
Coverage duration 1 year.
Erlotinib: For NSCLC, requires concurrent treatment with first‑line/maintenance/second+ line therapy after progression following at least one prior chemotherapy regimen; pancreatic cancer requires combination with gemcitabine; prescriber must be an oncologist.
Coverage duration 1 year.
Bexarotene: Capsule for cutaneous T‑cell lymphoma requires refractory disease to at least one prior systemic therapy; gel requires refractory/persistent after or intolerant of other therapies; prescriber: dermatologist or oncologist.
Coverage duration 1 year.
Nilotinib: Adults with CML‑CP not newly diagnosed and AP Ph+ CML require prior therapy that included imatinib; pediatric Ph+ CML‑CP and CML‑AP require prior TKI therapy.
Coverage duration 1 year.
Tazverik: EZH2 mutation‑positive follicular lymphoma requires prior treatment with at least two systemic therapies.
Coverage duration 1 year.
Tetrabenazine: Not covered in hepatic impairment, active suicidality or untreated/inadequately treated depression, or with MAO inhibitors or reserpine; CYP2D6 genotype documentation required for doses >50 mg/day.
Coverage duration 1 year.
Thalomid: Multiple myeloma coverage requires use in combination with dexamethasone; ENL with moderate‑to‑severe neuritis requires combination therapy.
Coverage duration 1 year.
Tibsovo: Coverage for cholangiocarcinoma requires previous treatment.
Coverage duration 1 year.
Tivdak: Recurrent or metastatic cervical cancer requires disease progression on or after chemotherapy.
Coverage duration 1 year.
Actemra: RA coverage requires diagnosis of moderately to severely active RA and trial of two listed agents; polyarticular JIA requires trial of two listed agents; systemic JIA requires trial of NSAID, systemic glucocorticoid, or methotrexate.
Reauthorization requires documentation of positive clinical response; coverage 1 year.
Trodelvy: For unresectable locally advanced/metastatic TNBC requires prior use of ≥2 systemic therapies with at least one for metastatic disease; for HR+/HER2‑ requires prior endocrine therapy and ≥2 additional systemic therapies in metastatic setting.
Coverage duration 1 year.
Truqap: HR+/HER2‑ advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations requires progression on ≥1 endocrine‑based regimen or recurrence within 12 months of adjuvant therapy and combination use with fulvestrant.
Coverage duration 1 year.
Tukysa: Advanced unresectable/metastatic HER2+ breast cancer requires trial of ≥1 prior anti‑HER2 regimen and combination with trastuzumab and capecitabine; RAS WT HER2+ metastatic CRC requires prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and combination with trastuzumab.
Coverage duration 1 year.
Tymlos: Requires documentation of BMD T‑score ≤ ‑2.5 AND trial of Jubbonti or Stoboclo and an oral bisphosphonate (or IV if intolerant).T‑score ≤ -2.5
Coverage duration 2 years.
Ubrelvy: Acute migraine treatment requires trial of ≥2 generic triptans unless contraindicated or not tolerated.trial of two triptans
Coverage duration 1 year.
Vanflyta: For newly diagnosed AML FLT3‑ITD positive requires use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation.
Coverage duration 1 year.
Venclexta: Newly diagnosed AML in adults ≥75 years or with comorbidities precluding intensive therapy requires combination with azacitidine, decitabine, or low‑dose cytarabine.
Coverage duration 1 year.
Veozah: Moderate‑to‑severe vasomotor symptoms due to menopause requires trial, failure, contraindication or intolerance to one preferred or generic medication for VMS.
Coverage duration 1 year.
Verquvo: Requires NYHA class II–IV AND LVEF <45% AND either prior HF hospitalization in prior 6 months OR outpatient IV diuretic in prior 3 months; must be taken with at least two background HF therapies (beta‑blocker, ACE/ARB/ARNI, SGLT2 approved for HF, mineralocorticoid) unless contraindicated.LVEF <45%
Coverage duration 1 year.